Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine.
Standard
Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine. / Barthell, Elisabeth; Wölber, Linn; Hellner, Karin; Camerer, Birka; Gieseking, Friederike; Hauschild, Maik; Mylonas, Ioannis; Friese, Klaus; Sings, Heather; Railkar, Radha; Gause, Christine; Barr, Eliav.
In: ARCH GYNECOL OBSTET, 2008.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine.
AU - Barthell, Elisabeth
AU - Wölber, Linn
AU - Hellner, Karin
AU - Camerer, Birka
AU - Gieseking, Friederike
AU - Hauschild, Maik
AU - Mylonas, Ioannis
AU - Friese, Klaus
AU - Sings, Heather
AU - Railkar, Radha
AU - Gause, Christine
AU - Barr, Eliav
PY - 2008
Y1 - 2008
N2 - INTRODUCTION: As limited data among German women exist about HPV, Chlamydia trachomatis (CT) and Neisseria gonorrhoeae, we report the prevalence of these genital infections and general baseline demographics of the young German women enrolled in the phase III trials of the quadrivalent HPV vaccine. MATERIALS AND METHODS: German females (n = 437; 9-23 years) were recruited among 3 international phase 3 studies of an HPV-6/11/16/18 vaccine. We present baseline characteristics, prevalence of HPV-6/11/16/18 and, for women aged 16-23, abnormal cervical cytology and sexually transmitted diseases. RESULTS: Chlamydia trachomatis and Neisseria gonorrhoeae prevalence was 5 and 0.3%, respectively. Approximately 17% of participants had HPV-6, 11, 16, or 18 DNA or antibodies. All subjects
AB - INTRODUCTION: As limited data among German women exist about HPV, Chlamydia trachomatis (CT) and Neisseria gonorrhoeae, we report the prevalence of these genital infections and general baseline demographics of the young German women enrolled in the phase III trials of the quadrivalent HPV vaccine. MATERIALS AND METHODS: German females (n = 437; 9-23 years) were recruited among 3 international phase 3 studies of an HPV-6/11/16/18 vaccine. We present baseline characteristics, prevalence of HPV-6/11/16/18 and, for women aged 16-23, abnormal cervical cytology and sexually transmitted diseases. RESULTS: Chlamydia trachomatis and Neisseria gonorrhoeae prevalence was 5 and 0.3%, respectively. Approximately 17% of participants had HPV-6, 11, 16, or 18 DNA or antibodies. All subjects
M3 - SCORING: Zeitschriftenaufsatz
JO - ARCH GYNECOL OBSTET
JF - ARCH GYNECOL OBSTET
SN - 0932-0067
ER -